Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas.
Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Mol Cancer Res. 2017 Oct;15(10):1331-1340. doi: 10.1158/1541-7786.MCR-17-0180. Epub 2017 Jul 6.
The progesterone receptor (PR) regulates transcriptional programs that drive proliferation, survival, and stem cell phenotypes. Although the role of native progesterone in the development of breast cancer remains controversial, PR clearly alters the transcriptome in breast tumors. This study identifies a class of genes, Interferon (IFN)-stimulated genes (ISGs), potently downregulated by ligand-activated PR which have not been previously shown to be regulated by PR. Progestin-dependent transcriptional repression of ISGs was observed in breast cancer cell line models and human breast tumors. Ligand-independent regulation of ISGs was also observed, as basal transcript levels were markedly higher in cells with PR knockdown. PR repressed ISG transcription in response to IFN treatment, the canonical mechanism through which these genes are activated. Liganded PR is robustly recruited to enhancer regions of ISGs, and ISG transcriptional repression is dependent upon PR's ability to bind DNA. In response to PR activation, key regulatory transcription factors that are required for IFN-activated ISG transcription, STAT2 and IRF9, exhibit impaired recruitment to ISG promoter regions, correlating with PR/ligand-dependent ISG transcriptional repression. IFN activation is a critical early step in nascent tumor recognition and destruction through immunosurveillance. As the large majority of breast tumors are PR positive at the time of diagnosis, PR-dependent downregulation of IFN signaling may be a mechanism through which early PR-positive breast tumors evade the immune system and develop into clinically relevant tumors. This study highlights a novel transcriptional mechanism through which PR drives breast cancer development and potentially evades the immune system. .
孕激素受体(PR)调节转录程序,驱动增殖、存活和干细胞表型。尽管天然孕激素在乳腺癌发生中的作用仍存在争议,但 PR 显然改变了乳腺癌肿瘤中的转录组。本研究确定了一类基因,即干扰素(IFN)刺激基因(ISGs),它们被配体激活的 PR 强烈下调,以前没有显示受 PR 调节。在乳腺癌细胞系模型和人类乳腺癌肿瘤中观察到孕激素依赖性 ISGs 的转录抑制。还观察到 ISGs 的配体非依赖性调节,因为 PR 敲低的细胞中基础转录水平明显更高。PR 通过经典的激活这些基因的机制,即 IFN 处理,抑制 ISG 转录。配体结合的 PR 被强烈募集到 ISGs 的增强子区域,并且 ISG 转录抑制依赖于 PR 结合 DNA 的能力。PR 激活后,需要用于 IFN 激活 ISG 转录的关键调节转录因子 STAT2 和 IRF9,其募集到 ISG 启动子区域的能力受损,这与 PR/配体依赖性 ISG 转录抑制相关。IFN 激活是通过免疫监视对新生肿瘤进行识别和破坏的关键早期步骤。由于在诊断时绝大多数乳腺癌肿瘤都是 PR 阳性,PR 依赖性 IFN 信号转导下调可能是早期 PR 阳性乳腺癌肿瘤逃避免疫系统并发展为临床相关肿瘤的机制。本研究强调了 PR 驱动乳腺癌发生并可能逃避免疫系统的一种新的转录机制。